NCT00015951View on ClinicalTrials.gov

Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2001

Primary Completion Date

April 30, 2003

Study Completion Date

March 31, 2004

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
BIOLOGICAL

bevacizumab

DRUG

cytarabine

DRUG

mitoxantrone hydrochloride

Trial Locations (3)

21201

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

30342-1601

Blood and Marrow Transplant Group of Georgia, Atlanta

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Maryland Greenebaum Cancer Center

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT00015951 - Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | Biotech Hunter | Biotech Hunter